Our current pipeline consists of new molecular entities with relevant mechanism of actions in skin diseases, targeting significant market opportunities in the global dermatology market.
Pipeline
OVERVIEW
PIPELINE
PRODUCT
CANDIDATE
CANDIDATE
MOA &
INDICATION
INDICATION
PRE-
CLINICAL
CLINICAL
PHASE
1
1
PHASE
2a
2a
PHASE
2b
2b
PHASE
3
3
